Companies › CASI pharmaceuticals
1 active drug program in 2 registered trials: 2 Phase 1; Hematology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CID-103 anti-CD38 monoclonal antibody | CD38 | Phase 1 | Chronic Immune Thrombocytopenia; Antibody Mediated Rejection | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07017725 | CID-103 | Phase 1 | Chronic Immune Thrombocytopenia | Hematology | Dec 2026 |
| NCT07641426 | CID-103 | Phase 1 | Antibody Mediated Rejection | Other | May 2030 |
Cash of $6m on 2025-12-31; operating cash outflow about $21m a year; runway about 3 months at that burn, to Apr 2026
Takeda Johnson & Johnson (Janssen) Zhejiang ACEA Pharmaceutical Biogen Sanofi Celltrion GSK Sinocelltech
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.